Clinical trials: Pulmonary Resistance
Metabolic Syndrome, Emotional Eating
The Relationship Between COVID-19 Anxiety Level and Emotional Eating in Individuals With Metabolic Syndrome
The aim was to determine the coronavirus anxiety levels and emotional eating status of cases with diagnosis of MetS according to diagnostic criteria published by the International Diabetic Federation (IDF) in 2005 and healthy…
- Conditions
- Metabolic Syndrome, Emotional Eating, COVID-19
- Trial name
- COVID-19 (NCT04912934)
- Testing
- A survey form was applied to individuals included in the study face-to-face.
- Where
- Turkey (Türkiye)
- Volunteers
- 214 people
- Sponsor
- Ordu University
NSCLC
De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
This study is based on the following hypothesis "De novo resistance to EGFR-TKI in EGFR mutation positive patients is related with mutations in EGFR downstream genes".
- Trial name
- NCT01697163
- Volunteers
- 155 people
- Sponsor
- Severance Hospital
Pneumonia
Study Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Telithromycin Once Daily for 7 Days, or Azithromycin Once Daily for 5 Days
A multinational, multicenter, randomized, double-blind, study in areas of high pneumococcal resistance comparing the clinical efficacy and health outcomes of outpatients with mild to moderate Community-Acquired Pneumonia (CAP)…
- Trial name
- COBRA II (NCT00237445)
- Testing
- telithromycin, azithromycin
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Sanofi
Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE
A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
This was a Phase 3 study containing a randomized open-label superiority cohort (Cohort 1) comparing the efficacy and safety of plazomicin with colistin when combined with a second antibiotic (either meropenem or tigecycline) in…
- Conditions
- Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE, Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE, Complicated Urinary Tract Infection (cUTI) Due to CRE
- Trial name
- CARE (NCT01970371)
- Testing
- plazomicin, colistin, meropenem
- Volunteers
- 69 people
- Sponsor
- Achaogen, Inc.
Pulmonary Disease, Tuberculosis, Pulmonary
A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults
A Phase 1, Drug-Drug Interaction Study to Evaluate the Safety, Tolerability, and the Induction Potential of TBAJ-876 on CYP3A4 and P-glycoprotein and the Inhibition Potential of TBAJ-876 on P-glycoprotein in Healthy Adult Subjects
- Conditions
- Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis
- Trial name
- NCT05526911
- Testing
- TBAJ-876, Midazolam, Digoxin
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Global Alliance for TB Drug Development
Carcinoma, Non-small-cell Lung
Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer
The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every three weeks in combination with docetaxel (Taxotere) in the treatment of patients with non-small cell lung cancer…
- Trial name
- NCT00047801
- Testing
- TLK286 in combination with docetaxel
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- Telik
Small Cell Lung Cancer
Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy
This Phase II study was designed to evaluate the safety and efficacy of albumin paclitaxel in combination with simvastatin compared with treatment with albumin paclitaxel alone in ES-SCLC patients relapsed from first-line…
- Trial name
- NCT04698941
- Testing
- Albumin Paclitaxel, Simvastatin
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Solid Tumor
SMP-3124LP in Adults With Advanced Solid Tumors
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
- Trial name
- NCT06526819
- Testing
- SMP3124LP
- Where
- 13 sites in United States, Japan
- Volunteers
- 120 people
- Sponsor
- Sumitomo Pharma America, Inc.
Asthma
Daily Magnesium-supplement for Severe Asthmatics
The present study is part of a project titled 'Magnesium in asthma and chronic obstructive pulmonary disease'. The hypothesis of the main project is that a daily magnesium supplement will benefit patients with asthma and chronic…
- Trial name
- NCT01113151
- Testing
- Mablet (Magnesium-supplement)
- Where
- Denmark
- Volunteers
- 5 people
- Sponsor
- University of Aarhus
Ventilator Acquired Pneumonia
Study to Determine Quicker Methods of Diagnosing Pneumonia Caused by a Breathing Machine in Critically Ill Patients
Critically ill patients on a breathing machine are at risk of developing a type of pneumonia called Ventilator Acquired Pneumonia (VAP).
- Trial name
- NCT00938002
- Testing
- Acceler8 Pheno
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Denver Health and Hospital Authority
Small-cell Lung Cancer
Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)
The main purpose of this study is to assess efficacy, safety, tolerability and pharmacokinetics (PK) of Berzosertib in combination with Topotecan in participants with relapsed, platinum-resistant small-cell lung cancer (SCLC).
- Trial name
- NCT04768296
- Testing
- Berzosertib, Topotecan
- Where
- 51 sites in United States, Belgium and 5 more
- Volunteers
- 76 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma
Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations
This phase II trial studies how well targeted therapy works in treating patients with incurable non-small cell lung cancer with a genetic mutation.
- Conditions
- EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
- Trial name
- NCT02949843
- Testing
- Chemotherapy, Immunotherapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Wake Forest University Health Sciences
Lung Neoplasms
Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer
The mechanisms of sensitivity and resistance to oncogene-targeted therapy can be determined from tumor tissue or tumor cell lines derived from available archival samples and/or from standard-of-care re-biopsy upon suspected tumor…
- Trial name
- NCT01580982
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of Colorado, Denver
Pneumonia, Pneumococcal, Community-acquired Pneumonia
Quantitative Polymerase Chain Reaction for Improved Detection of Pneumococci in CAP "CAPTAIN"
The purpose of this study is to evaluate the added diagnostic value of a quantitative polymerase chain reaction targeting the lytA gene in detecting pneumococci in patients with community-acquired pneumonia.
- Trial name
- CAPTAIN (NCT03315403)
- Testing
- LytA targeted quantitative polymerase chain reaction (qPCR)
- Where
- 2 sites in Netherlands
- Volunteers
- 922 people, healthy volunteers welcome
- Sponsor
- Medical Center Alkmaar
CF - Cystic Fibrosis, Klebsiella Pneumoniae Infection
Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections
This is a Phase 1, open-label, multi-center pilot study evaluating the safety and microbiological activity of intravenous (IV) bacteriophage therapy in combination with standard IV antibiotics in adults with cystic fibrosis (CF)…
- Conditions
- CF - Cystic Fibrosis, Klebsiella Pneumoniae Infection, E Coli Infections, Staphylococcus Aureus Infection
- Trial name
- NCT07280598
- Testing
- Intravenous Bacteriophage Cocktail plus Standard IV Antibiotics
- Volunteers
- 30 people
- Sponsor
- University of California, San Diego
Non-small Cell Lung Cancer, EGFR Mutant Advanced Non-small Cell Lung Cancer
Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis
The goal of this clinical trial is to learn if the combination therapy with SKB264 and anlotinib works to treat EGFR-TKI-resistant, liver-metastatic non-squamous non-small cell lung cancer (NSCLC).
- Trial name
- NCT07545213
- Testing
- SKB264
- Where
- China
- Volunteers
- 27 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
PAH
PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)
This is a multicenter double-blind, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of 2 doses of CXA-10 on stable background therapy in 96 subjects 18 to 80 years of age with PAH.
- Trial name
- PAH (NCT03449524)
- Testing
- 75mg CXA-10, 150mg CXA-10
- Where
- 46 sites in United States, United Kingdom
- Volunteers
- 69 people
- Sponsor
- Complexa, Inc.
Disease Progression
Treatment Resistance Following Anti-cancer Therapies
The TRANSLATE study aims to better understand why tumors become resistant to standard anti-cancer therapies. New tumor biopsy and blood samples are collected after disease progression on standard-of-care anti-cancer treatment and…
- Trial name
- NCT04436120
- Testing
- De novo tumor tissue biopsy, Research blood draws
- Where
- 33 sites in United States, Argentina and 3 more
- Volunteers
- 38 people
- Sponsor
- Pfizer
NSCLC (Advanced Non-small Cell Lung Cancer)
QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC
Lung cancer is the leading cause of cancer-related deaths worldwide. According to the 2023 global cancer statistics, there are approximately 2.47 million new cases and 1.76 million deaths of lung cancer annually, accounting for…
- Trial name
- NCT07330596
- Testing
- QL1706 combined with Chemotherapy, Chemotherapy
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Anhui Provincial Cancer Hospital
Non Small Cell Lung Cancer Squamous (NSCLC-Sq), Head and Neck Squamous Cell Carcinoma (HNSCC)
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
To assess safety and tolerability, describe the dose-limiting toxicities, assess the preliminary antitumor activity, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in…
- Conditions
- Non Small Cell Lung Cancer Squamous (NSCLC-Sq), Head and Neck Squamous Cell Carcinoma (HNSCC), Small Cell Lung Cancer (SCLC), Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- NCT03811652
- Testing
- MEDI7247
- Where
- 3 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- MedImmune LLC